US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Shattuck Labs, Inc. - Common Stock (NQ:STTK)

5.560 -0.160 (-2.80%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Shattuck Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML)
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Recap: Shattuck Labs Q3 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For Shattuck Labs ↗
 
Via Benzinga
News headline image
Shattuck Labs: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 9, 2023 ↗
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
News headline image
Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations for Shattuck Labs's Future ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Shattuck Labs ↗
 
Via Benzinga
News headline image
Shattuck Labs's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
News headline image
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
News headline image
Why Biophytis Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket ↗
Gainers FaZe Holdings Inc. (NASDAQ: FAZE) shares rose 64.7% to $0.2520 in pre-market trading after falling over 4% on Friday. 
Via Benzinga
News headline image
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
7 Very Undervalued Penny Stocks to Buy in April 2023 ↗
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option. 
Via InvestorPlace
News headline image
Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank ↗
The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... 
Via Benzinga
News headline image
Shattuck Labs Announces Participation in Upcoming March Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming SVB Securities Global Biopharma Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 23, 2023 ↗
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >